Apixaban (Eliquis) Dosing for Elderly Patients
For elderly patients with atrial fibrillation, start with apixaban 5 mg twice daily, and reduce to 2.5 mg twice daily ONLY if the patient meets at least 2 of these 3 criteria: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL. 1
Atrial Fibrillation Stroke Prevention
Standard Dosing Approach
The FDA-approved dosing is clear and evidence-based from the ARISTOTLE trial 2, 1:
- Most patients (including those 65-79 years): 5 mg twice daily
- Dose reduction to 2.5 mg twice daily requires meeting at least 2 of 3 criteria:
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL (133 μmol/L)
Critical Point: Age Alone Does Not Trigger Dose Reduction
Being elderly (65-79 years) or even very elderly (≥80 years) by itself does NOT warrant dose reduction. 3 The ARISTOTLE trial demonstrated that patients with only ONE dose-reduction criterion (including age ≥80 years alone) who received the standard 5 mg twice daily dose had:
- Similar efficacy for stroke prevention (HR 0.94 vs warfarin) 3
- Similar safety profile for major bleeding (HR 0.68 vs warfarin) 3
- Consistent benefits across the age spectrum 4, 5
Renal Function Considerations in the Elderly
For patients with CrCl 30-49 mL/min: Continue 5 mg twice daily unless they meet 2 of the 3 dose-reduction criteria 6. The Canadian guidelines suggest considering 2.5 mg twice daily in this renal range, but emphasize this is based on meeting the composite criteria, not renal function alone 6.
For patients with CrCl 15-29 mL/min: Very limited trial data exists. The ARISTOTLE trial included only 1.5% of patients with CrCl as low as 25 mL/min 6. Clinical judgment is required, but if used, apply the standard dose-reduction criteria.
Common Pitfall: Inappropriate Underdosing
Avoid empiric dose reduction based on age alone or clinical "gestalt." A real-world study found 17% of patients received off-label reduced dosing, with 15% being "underdosed" 7. While this study showed no significant difference in stroke or bleeding outcomes, underdosing may compromise efficacy without proven safety benefit. The mortality was actually higher in the underdosed group (10.9% vs 1.4%), though this likely reflects confounding by indication 7.
Venous Thromboembolism Treatment
Acute Treatment Phase (First 7 Days)
10 mg twice daily for 7 days, regardless of age 1. No dose adjustment criteria apply during acute VTE treatment, even in very elderly patients.
Continuation Phase (After 7 Days)
5 mg twice daily for the remainder of treatment (typically 3-6 months minimum) 1. Again, no age-based dose adjustments.
Extended/Secondary Prevention
2.5 mg twice daily after completing at least 6 months of treatment for DVT/PE 1. This lower dose is specifically for extended prophylaxis against recurrence, not based on patient characteristics. Recent evidence supports this approach even in provoked VTE with enduring risk factors, showing 87% relative risk reduction in recurrent VTE (HR 0.13) with minimal bleeding risk 8.
Practical Algorithm for Elderly AF Patients
- Calculate CrCl (use actual body weight in Cockcroft-Gault)
- Check if CrCl <15 mL/min or on dialysis: Consider alternative anticoagulation; limited data for apixaban
- Count dose-reduction criteria present:
- Age ≥80? (Yes = 1 point)
- Weight ≤60 kg? (Yes = 1 point)
- Serum creatinine ≥1.5 mg/dL? (Yes = 1 point)
- If ≥2 criteria present: Use 2.5 mg twice daily 9, 2
- If 0-1 criteria present: Use 5 mg twice daily 9, 2
Drug Interactions Requiring Dose Adjustment
If patient is on combined P-glycoprotein AND strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin):
- Reduce 5 mg twice daily → 2.5 mg twice daily
- If already on 2.5 mg twice daily → avoid apixaban 1
Evidence Quality Note
The dose-reduction criteria are derived from the ARISTOTLE trial, which showed that the 2.5 mg twice daily dose in patients with ≥2 criteria achieved similar apixaban exposure and clinical outcomes as the 5 mg dose in standard patients 4. The pharmacokinetic analysis confirmed appropriate drug levels despite lower dosing, with consistent reductions in stroke (HR 0.79), major bleeding (HR 0.69), and mortality (HR 0.89) compared to warfarin across all subgroups 10.